LT2820016T - N-(5s, 6s, 9r)-5-amino-6-(2, 3-difluorfenil) -6,7,8, 9-tetrahidro-5h-ciklohepta[b]piridin-9-il- 4-(2-okso-2, 3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilatas, hemisulfato druska - Google Patents

N-(5s, 6s, 9r)-5-amino-6-(2, 3-difluorfenil) -6,7,8, 9-tetrahidro-5h-ciklohepta[b]piridin-9-il- 4-(2-okso-2, 3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilatas, hemisulfato druska

Info

Publication number
LT2820016T
LT2820016T LTEP13708603.9T LT13708603T LT2820016T LT 2820016 T LT2820016 T LT 2820016T LT 13708603 T LT13708603 T LT 13708603T LT 2820016 T LT2820016 T LT 2820016T
Authority
LT
Lithuania
Prior art keywords
pyridin
cyclohepta
imidazo
difluorophenyl
tetrahydro
Prior art date
Application number
LTEP13708603.9T
Other languages
English (en)
Lithuanian (lt)
Inventor
Daniel Richard Roberts
Richard Raymond Schartman
Chenkou Wei
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47844498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2820016(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of LT2820016T publication Critical patent/LT2820016T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LTEP13708603.9T 2012-02-27 2013-02-25 N-(5s, 6s, 9r)-5-amino-6-(2, 3-difluorfenil) -6,7,8, 9-tetrahidro-5h-ciklohepta[b]piridin-9-il- 4-(2-okso-2, 3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilatas, hemisulfato druska LT2820016T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261603598P 2012-02-27 2012-02-27
PCT/US2013/027648 WO2013130402A1 (en) 2012-02-27 2013-02-25 N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b] pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b] pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt

Publications (1)

Publication Number Publication Date
LT2820016T true LT2820016T (lt) 2017-10-25

Family

ID=47844498

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP13708603.9T LT2820016T (lt) 2012-02-27 2013-02-25 N-(5s, 6s, 9r)-5-amino-6-(2, 3-difluorfenil) -6,7,8, 9-tetrahidro-5h-ciklohepta[b]piridin-9-il- 4-(2-okso-2, 3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilatas, hemisulfato druska
LTEP17180587.2T LT3254681T (lt) 2012-02-27 2013-02-25 N-(5s,6s,9r)-5-amino-6-(2,3-difluorfenil)-6,7,8,9-tetrahidro-5h-ciklohepta[b]piridin-9-il-4-(2-okso-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilato druska

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP17180587.2T LT3254681T (lt) 2012-02-27 2013-02-25 N-(5s,6s,9r)-5-amino-6-(2,3-difluorfenil)-6,7,8,9-tetrahidro-5h-ciklohepta[b]piridin-9-il-4-(2-okso-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilato druska

Country Status (26)

Country Link
US (1) US8759372B2 (enExample)
EP (2) EP3254681B1 (enExample)
JP (2) JP6208154B2 (enExample)
KR (2) KR102220969B1 (enExample)
CN (1) CN104136437B (enExample)
AU (1) AU2013226361B2 (enExample)
BR (1) BR112014021032B1 (enExample)
CA (1) CA2865585C (enExample)
CY (2) CY1119448T1 (enExample)
DK (2) DK2820016T3 (enExample)
EA (1) EA025358B1 (enExample)
ES (2) ES2746031T3 (enExample)
HK (1) HK1248111B (enExample)
HR (2) HRP20171620T1 (enExample)
HU (2) HUE047050T2 (enExample)
IL (1) IL234272B (enExample)
LT (2) LT2820016T (enExample)
MX (1) MX352171B (enExample)
NO (1) NO2935439T3 (enExample)
PL (2) PL2820016T3 (enExample)
PT (2) PT2820016T (enExample)
RS (2) RS56556B1 (enExample)
SG (1) SG11201404834XA (enExample)
SI (2) SI2820016T1 (enExample)
SM (1) SMT201700489T1 (enExample)
WO (1) WO2013130402A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108997490A (zh) 2012-01-26 2018-12-14 克里斯托弗·J·索尔斯 肽激素的降钙素cgrp家族的肽拮抗剂和它们的用途
WO2013130402A1 (en) * 2012-02-27 2013-09-06 Bristol-Myers Squibb Company N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b] pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b] pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
KR102363946B1 (ko) 2015-03-06 2022-02-17 아테아 파마슈티컬즈, 인크. HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드
US11390654B2 (en) * 2016-09-02 2022-07-19 Christopher Joseph Soares Use of CGRP receptor antagonists in neuroprotection and neurological disorders
HRP20220278T1 (hr) 2016-09-07 2022-05-13 Atea Pharmaceuticals, Inc. 2'-supstituirani-n6-supstituirani purinski nukleotidi za liječenje bolesti izazvanih rnk virusima
IL295609B2 (en) * 2017-02-01 2023-11-01 Atea Pharmaceuticals Inc Nucleotide hemisulfate salt for the treatment of hepatitis C virus
DK4088720T3 (da) * 2018-03-25 2025-09-29 Pfizer Ireland Pharmaceuticals Unlimited Company Rimegepant til cgrp-relaterede lidelser
WO2019200005A1 (en) 2018-04-10 2019-10-17 Atea Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis
MX2021008191A (es) * 2019-01-20 2021-08-11 Biohaven Pharm Holding Co Ltd Antagonistas del péptido relacionado con el gen de calcitonina (cgrp) para el tratamiento de la irrupción de migraña.
WO2020252368A2 (en) * 2019-06-14 2020-12-17 The Regents Of The University Of California New therapeutic approach to lung disease
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び／又は発生の低減
MX2023014898A (es) 2021-06-17 2024-04-29 Atea Pharmaceuticals Inc Terapia combinada anti-vhc ventajosa.
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
AR126954A1 (es) * 2021-09-02 2023-12-06 Biohaven Pharm Holding Co Ltd Métodos para tratar la psoriasis con uno o más antagonistas de receptores de cgrp
CN115850266A (zh) * 2021-09-26 2023-03-28 奥锐特药业(天津)有限公司 瑞美吉泮新晶型及其制备方法
CN116554164B (zh) * 2022-01-27 2025-10-03 奥锐特药业(天津)有限公司 一种瑞美吉泮的制备方法
WO2023175632A1 (en) * 2022-03-17 2023-09-21 Msn Laboratories Private Limited, R&D Center Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof
WO2024180562A1 (en) * 2023-03-02 2024-09-06 Natco Pharma Limited A process for the preparation of pure crystalline rimegepant and its salts thereof
WO2025193980A2 (en) * 2024-03-13 2025-09-18 CNS Biosciences, Inc. Method of treating neuropathic pain using an anti-cgrp inhibitor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24500A1 (fr) * 1997-03-21 1998-10-01 Lg Life Sciences Ltd Derive du sel d'acide carboxylique de naphthyridine .
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
CN1930145B (zh) 2004-03-05 2011-06-15 Msdk.K.公司 环烷吡啶衍生物
US8039460B2 (en) 2004-10-13 2011-10-18 Merck Sharp & Dohme Corp. CGRP receptor antagonists
WO2006047196A2 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. Cgrp receptor antagonists
WO2007120590A2 (en) 2006-04-10 2007-10-25 Merck & Co., Inc. Process for the preparation of pyridine heterocycle cgrp antagonist intermediate
DE102006017827A1 (de) * 2006-04-13 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue kristalline Verbindungen
US8143403B2 (en) 2008-04-11 2012-03-27 Bristol-Myers Squibb Company CGRP receptor antagonists
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US8314117B2 (en) * 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8669368B2 (en) 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
US8748429B2 (en) 2011-04-12 2014-06-10 Bristol-Myers Squibb Company CGRP receptor antagonists
WO2013130402A1 (en) * 2012-02-27 2013-09-06 Bristol-Myers Squibb Company N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b] pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b] pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt

Also Published As

Publication number Publication date
JP6208154B2 (ja) 2017-10-04
PL3254681T3 (pl) 2019-12-31
AU2013226361A1 (en) 2014-10-16
EP3254681B1 (en) 2019-06-19
CY1119448T1 (el) 2018-03-07
SI2820016T1 (sl) 2017-11-30
DK3254681T3 (da) 2019-09-30
EP2820016B1 (en) 2017-08-02
JP6476253B2 (ja) 2019-02-27
AU2013226361B2 (en) 2017-09-21
MX352171B (es) 2017-11-13
EA025358B1 (ru) 2016-12-30
SMT201700489T1 (it) 2017-11-15
ES2642737T3 (es) 2017-11-17
CA2865585A1 (en) 2013-09-06
MX2014009544A (es) 2014-11-10
PL2820016T3 (pl) 2018-01-31
EA201491585A1 (ru) 2015-01-30
KR102076118B1 (ko) 2020-02-11
SI3254681T1 (sl) 2019-10-30
SG11201404834XA (en) 2014-09-26
CY1122121T1 (el) 2020-11-25
CN104136437A (zh) 2014-11-05
CA2865585C (en) 2019-12-10
HRP20191655T1 (hr) 2019-12-13
DK2820016T3 (da) 2017-11-13
CN104136437B (zh) 2016-05-11
HRP20171620T1 (hr) 2017-12-01
BR112014021032A2 (enExample) 2017-06-20
NO2935439T3 (enExample) 2018-03-31
JP2017226693A (ja) 2017-12-28
EP3254681A1 (en) 2017-12-13
KR102220969B1 (ko) 2021-02-25
HK1248111B (en) 2020-04-17
EP2820016A1 (en) 2015-01-07
WO2013130402A1 (en) 2013-09-06
LT3254681T (lt) 2019-09-25
ES2746031T3 (es) 2020-03-04
RS59295B1 (sr) 2019-10-31
HUE034936T2 (hu) 2018-03-28
IL234272B (en) 2018-10-31
RS56556B1 (sr) 2018-02-28
KR20200016993A (ko) 2020-02-17
BR112014021032B1 (pt) 2022-09-27
PT2820016T (pt) 2017-10-18
KR20140130140A (ko) 2014-11-07
US8759372B2 (en) 2014-06-24
PT3254681T (pt) 2019-10-01
US20130225636A1 (en) 2013-08-29
HUE047050T2 (hu) 2020-04-28
JP2015511581A (ja) 2015-04-20

Similar Documents

Publication Publication Date Title
IL234272B (en) The mesosulfate salt of n – (r9, s6, s5) – 5 amino – 6 – (2, 3 – difluorophenyl) – 6, 7, 8, 9, – tetrahydro – h5 – cyclohepta [b] pyridine – 9 – yl – 4 – (2-oxo-2,3,dihydro-h1-imidazo[5,4-b]pyridine-1-yl)piperidine-1-carboxylate
ZA201906379B (en) 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
IL227496B (en) Pyrazolo[4,3–b]pyridines are converted as drugs
IL224903A (en) Imidzo [c – 5,4] quinolines as DNA inhibitors
ZA201209632B (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
ZA201405070B (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
IL240397A0 (en) Forms of methyl {6,4-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo [[b-4,3-pyridino-3-yl]pyrimidino-5-yl} methyl carbamate
ZA201307783B (en) Tri-and tetracylic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent
ZA201409299B (en) Risperidone or paliperidone implant formulation
IL221479A0 (en) Triazolo [4,5-b] pyridin derivatives
IL233066A0 (en) Method for producing 1-(2-fluorobenzyl)-h1-pyrazolo [b-3,4]pyridine-3-formamidine hydrochloride
SG11201408816QA (en) 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
SG11201500883YA (en) 5-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
SI2697223T1 (sl) Derivati 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido(1,2-A)indol-ocetne kisline in njihova uporaba kot modulatorji prostaglandinskega receptorja D2
EP2651937B8 (en) Imidazo[4,5-c]quinolin-1-yl derivative useful in therapy